ASTRA STUDY (Angioplasty, Stent X-ray Intensive Antithrombotic Therapy) A PHASE III, PROSPECTIVE AND RANDOMIZED, MULTICENTER STUDY, OPEN LABEL, PARALLEL-GROUP, BLINDED ADJUDICATION, TO INVESTIGATE THE EFFECTIVENESS Of BRACHYTHERAPY IN THE REDUCTION OF RESTENOSIS AFTER FEMURAL AND POPLITEAL ARTERIES ANGIOPLASTY WITH OR WITHOUT SELECTIVE STENTING AND/OR INTENSIVE ANTITHROMBOTIC THERAPY IN PATIENTS WITH PERIPHERAL ORGANIC ARTHERY DISEASE OF THE INFERIOR LIMBS (FONTAINE-LERICHE STAGE IIb-IV)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002251-41-IT

Enrollment

320

Registered

2005-06-27

Start date

2005-03-22

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PAOD (Fontaine-Leriche St. IIb-IV)requiring percutaneous angioplasty with or without stenting MedDRA version: 6.1 Level: PT Classification code 10016426

Interventions

Product Name: NA Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: Acetylsalycilic acid Current Sponsor code: NA Concentration unit: mg milligram(s) Concentration type: equal Concentra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026